Lexicon Pharmaceuticals Q2 2020 Earnings Report
Key Takeaways
Lexicon Pharmaceuticals reported a decrease in revenues to $9.2 million, primarily due to a decrease of bulk tablet sales of XERMELO to Ipsen and collaborative revenues, partially offset by an increase in U.S. net product revenue. Net loss was $69.1 million, or $0.65 per share, as compared to a net loss of $23.0 million, or $0.22 per share, in the corresponding period in 2019. XERMELO U.S. net sales were $9.0 million, up 21% from the prior year quarter.
XERMELO U.S. net sales increased by 21% compared to the prior-year period.
Screening of patients initiated in the Phase 2 RELIEF-DPN-1 study for LX9211 in patients with diabetic peripheral neuropathic pain.
Revenues decreased to $9.2 million from $9.7 million for the corresponding period in 2019.
Net loss was $69.1 million, or $0.65 per share, as compared to a net loss of $23.0 million, or $0.22 per share, in the corresponding period in 2019.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Revenue by Segment
Forward Guidance
Anticipated Near-Term Milestones include dosing of first patient in the Phase 2 LX9211 study in diabetic peripheral neuropathic pain in Q3 2020 and initiation of a Phase 2 study for LX9211 in post-herpetic neuralgia in Q4 2020.
Positive Outlook
- Dosing of first patient in the Phase 2 LX9211 study in diabetic peripheral neuropathic pain in Q3 2020
Revenue & Expenses
Visualization of income flow from segment revenue to net income